Journal Watch · Journal of Medicinal Chemistry · 2026
Identification and Optimization of Pyridone Derivatives as Pan-MEK/RAF Nondegrading Molecular Glues for the Treatment of RAS-Driven Cancers.
Taken together, these findings suggest that compound <b>D56</b> is a potent pan-MEK/RAF nondegrading molecular glue for treating RAS-driven cancers.
TL;DR
Taken together, these findings suggest that compound <b>D56</b> is a potent pan-MEK/RAF nondegrading molecular glue for treating RAS-driven cancers.
Key findings
- Taken together, these findings suggest that compound <b>D56</b> is a potent pan-MEK/RAF nondegrading molecular glue for treating RAS-driven cancers.
What they did
Furthermore, protein-protein interaction (PPI) assays demonstrated that <b>D56</b> induces MEK1-BRAF and MEK1-CRAF complexes formation at low concentrations, indicating that <b>D56</b> is a potent MEK/RAF molecular glue. <b>D56</b> possesses an excellent selectivity over other 332 human-related kinases at 1 μM. Most importantly, in AsPC-1, HCT116, and OCI-AML-3 mouse xenograft models, <b>D56</b> achieved significant tumor growth inhibition.
Full abstract (original)
Background: In this study, we describe a series of pyridone derivatives as pan<b>-</b>MEK/RAF nondegrading molecular glues. Through investigation of the metabolic sites of the reported MEK/RAF inhibitor <b>16b</b>, rational design and systematic SAR studies led to the discovery of compound <b>D56</b>, which exhibits well-balanced <i>in vitro</i> and <i>in vivo</i> potency. <b>D56</b> could effectively block MEK and ERK phosphorylation with IC<sub>50</sub> values of 0.379 and 0.015 nM, respectively.
What they did: Furthermore, protein-protein interaction (PPI) assays demonstrated that <b>D56</b> induces MEK1-BRAF and MEK1-CRAF complexes formation at low concentrations, indicating that <b>D56</b> is a potent MEK/RAF molecular glue. <b>D56</b> possesses an excellent selectivity over other 332 human-related kinases at 1 μM. Most importantly, in AsPC-1, HCT116, and OCI-AML-3 mouse xenograft models, <b>D56</b> achieved significant tumor growth inhibition.
Results & conclusions: Taken together, these findings suggest that compound <b>D56</b> is a potent pan-MEK/RAF nondegrading molecular glue for treating RAS-driven cancers.
Abstract © the authors / Journal of Medicinal Chemistry (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1021/acs.jmedchem.6c00242 · PubMed 42098597.
Why it matters for pharma & biotech
- Directly relevant to teams in small-molecule drug discovery — the abstract reports new data in that space, so competitive and pipeline teams should read the full text.
- As earlier-stage work, its near-term value is target validation and assay design rather than clinical decisions.
- For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.
Modalities & themes detected: small-molecule drug discovery
Limitations & what to check in the full text
- This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
- The work is preclinical. Results in animal or cell models frequently do not translate directly to human efficacy or safety.
- The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.
Frequently asked questions
What did this Journal of Medicinal Chemistry study find?
Taken together, these findings suggest that compound <b>D56</b> is a potent pan-MEK/RAF nondegrading molecular glue for treating RAS-driven cancers.
What type of study is this?
It is a preclinical (animal / model) study, published in Journal of Medicinal Chemistry in 2026. Furthermore, protein-protein interaction (PPI) assays demonstrated that <b>D56</b> induces MEK1-BRAF and MEK1-CRAF complexes formation at low concentrations, indicating that <b>D56</b> is a potent MEK/RAF molecular glue.
Where can I read the original paper?
The original is at the publisher via DOI 10.1021/acs.jmedchem.6c00242. PubMed ID: 42098597. BioStudioAI reproduces the abstract for discussion and links to the source.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/identification-and-optimization-of-pyridone-derivatives-as-pan-mek-raf-n-c00242/
Reading papers is step one. Analysing the data is the work.
BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.
Open BioStudioAI More guides